SEPMAG wins Chinese patent for the World’s first homogenous biomagnetic separator system
Chinese diagnostic company, CapitalBio buys Sepmag Q250ml for production of IVD kits
January 24, 2011 – SEPMAG, the manufacturer of world leading biomagnetic separation systems for the in vitro diagnostics market, today celebrated receipt of a Chinese patent for the Company’s innovative homogenous magnetophoresis technology – issued by China’s State Intellectual Property Office (SIPO). This milestone achievement forms part of SEPMAG’s commercial strategy for targeting the Chinese market.
The patent was granted for SEPMAG’s unique methods and devices for the homogenious separation of magnetic particles - a technique that applies less pressure on particles and guarantees users consistently reproducable results in their in vitro diagnostics kits.
Furthermore, SEPMAG has already commenced shipping the SEPMAG Q250ml to CapitalBio, its first client in the region, for the processing of large batch volumes in protein purification. Following the success of this contract, SEPMAG intends to actively market itself to dignostic companies across China looking for more sophisticated solutions that allow for greater sensitivity, as an alternative to traditional technologies like Enzyme-Linked ImmunoSorbent Assays (ELISA).
SEPMAG’s precision magnetophoresis systems, unlike other biomagnetic separation processes, produce a completely homogeneous magnetic field, which applies the same magnetic force on beads regardless of the distance from the magnetic ring. Using conventional separators, beads that are further away from the magnet will be harder to manipulate and those that are closer may experience an excessive force, often resulting in bead aggregation, loss of activity and resuspension problems. In contrast, SEPMAG’S unique magnet alignment vastly reduces the variability of the end product, enables a more straightforward scale-up process and greatly simplifies revalidation processes .
Josep Maria Simó, CEO of SEPMAG, commented: “We are delighted that the Chinese Patent Office has granted SEPMAG a patent for our unique magnetophoresis techniques. This will allow us to further consolidate our Far-East presence, having already established a strong and growing foothold in Japan. Over the next couple of years, we forecast the Chinese marketplace to be amongst the fastest growing for biomagnetic separation systems. The agreement we have signed with CapitalBio marks the start of a significant expansion in the region and a continuation of the internationalisation of SEPMAG technologies.”
SEPMAG develops, manufactures and markets homogenous biomagnetic separation equipment for the international diagnostics market. . Its systems enhance the reproducibility of diagnostic kits, reduce material waste, facilitate the validation process and increase the safety of operation. These benefits are applicable through a range of laboratory settings from R&D through to large scale production. The company is headquartered in the Vallès Technology Park, Barcelona and has a U.S. subsidiary in Atlanta (GA).
Our product range includes the Stepmag, Sepmag Q and Sepmag LAB series, as well as the QCR monitoring system to control the process